title: External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.
abstract: This review shows the current analytical quality for the following analytes used as tumour markers in the external quality assessment (EQA)-programmes of Instand e.V., a national EQA-organiser in Germany: Corticotropin (ACTH), growth hormone (GH, hGH), prolactin (PRL), chorionic gonadotropin (CG, hCG), calcitonin (CT, hCT), thyroglobulin (Tg), carcinoembryonic antigen (CEA), CA-Antigens 125, 72-4, 15-3 and 19-9, alpha foetoprotein (AFP) and prostate-specific antigen (PSA). The results from the participants show a large variation in the precision of the methods used as well as in the comparability of results between methods for the same analyte. In general, the hormones used as tumour markers show better performance than the "CA-markers", which are often inadequately standardised and defined. In the case of one CA-marker (CA 72-4/TAG 72-4), the differences between the lowest kit median concentration and highest kit median concentration for one sample pair were 440% and 580%. The corresponding figures for ACTH were 123% and 156% and for CEA 180% and 184%. The classical tumour markers such as carcinoembryonic antigen (CEA) and alpha foetoprotein (AFP) performed markedly better than the CA-markers and PSA with regards to both inter- and intra-method comparability. The inter-laboratory precision for a given kit and marker was acceptable in many cases. The results show that only results from the same kit/method for each tumour marker can be used for cumulative or time-dependent comparison of results - for example pre-operative and post-operative follow up. In the case of prostate specific antigen (PSA), the kits used for free and total PSA must come from the same producer, if the generally accepted ratios are to have any diagnostic value. The need for kit- and laboratory-specific reference ranges and cut-off values for setting diagnostic specificity and sensitivity is highlighted from the EQA-results. The situation for inter-method comparability for the CA-Markers has not improved over the past decade. With the exception of calcitonin for detecting medullary thyroid carcinoma, chorionic gonadotropin in germ-cell tumours in men and thyroglobulin after total thyroidectomy, none of the remaining analytes appear to be suitable for screening purposes.
authors.affiliation: Instand Reference Laboratory, Instand e.V., Düsseldorf, Germany.
authors.forename: Hans
authors.initials: H
authors.lastname: Reinauer
authors.forename: William Graham
authors.initials: WG
authors.lastname: Wood
references.citation: Eur J Clin Chem Clin Biochem. 1991 Dec;29(12):787-94
references.pmid: 1724606
references.citation: J Clin Invest. 1968 Dec;47(12):2725-51
references.pmid: 4302180
references.citation: Ann Clin Biochem. 2004 Sep;41(Pt 5):370-7
references.pmid: 15333188
references.citation: Gynecol Oncol. 2001 Nov;83(2):177-85
references.pmid: 11606070
references.citation: Am J Hum Genet. 1992 Jun;50(6):1235-42
references.pmid: 1598904
references.citation: Cancer Sci. 2004 Jul;95(7):559-63
references.pmid: 15245590
references.citation: Am J Pathol. 1991 Feb;138(2):455-63
references.pmid: 1992770
references.citation: Acta Physiol Scand. 1961 Apr;51:348-55
references.pmid: 13697529
references.citation: Gastroenterology. 1978 Dec;75(6):1109-14
references.pmid: 309417
references.citation: Cancer Res. 1995 Oct 15;55(20):4570-4
references.pmid: 7553631
references.citation: CA Cancer J Clin. 1999 Sep-Oct;49(5):264-81
references.pmid: 11198954
references.citation: J Clin Invest. 1981 Nov;68(5):1331-7
references.pmid: 7028788
references.citation: Pathol Res Pract. 1996 Jul;192(7):684-93
references.pmid: 8880869
references.citation: Clin Chem. 1995 Aug;41(8 Pt 1):1115-20
references.pmid: 7543033
references.citation: J Urol. 2004 Oct;172(4 Pt 1):1297-301
references.pmid: 15371827
references.citation: J Exp Med. 1965 Mar 1;121:439-62
references.pmid: 14270243
references.citation: Br J Cancer. 1968 Jun;22(2):253-7
references.pmid: 4298235
references.citation: Int J Biol Markers. 1994 Apr-Jun;9(2):75-81
references.pmid: 7523545
references.citation: Trans Assoc Am Physicians. 1968;81:92-103
references.pmid: 5721413
references.citation: N Engl J Med. 2004 Aug 5;351(6):533-42
references.pmid: 15295046
references.citation: Clin Chim Acta. 1975 Jun 20;61(3):297-308
references.pmid: 1149257
references.citation: J Clin Lab Anal. 1995;9(4):252-60
references.pmid: 7562243
references.citation: N Engl J Med. 1968 Aug 8;279(6):279-83
references.pmid: 5660301
references.citation: Steroids. 1969 Jun;13(6):731-7
references.pmid: 5815274
references.citation: Laryngoscope. 2004 Aug;114(8):1346-54
references.pmid: 15280706
references.citation: Clin Chim Acta. 1971 Mar;32(1):41-51
references.pmid: 4328880
references.citation: Lab Res Methods Biol Med. 1983;8:269-82
references.pmid: 6196588
references.citation: Gan. 1984 Jun;75(6):540-7
references.pmid: 6468839
references.citation: Am J Pathol. 2004 Aug;165(2):565-76
references.pmid: 15277230
references.citation: Eur J Clin Chem Clin Biochem. 1993 Feb;31(2):75-82
references.pmid: 8467012
references.citation: Gan To Kagaku Ryoho. 1988 Sep;15(9):2761-6
references.pmid: 2458074
references.citation: Cancer Res. 1991 Jan 1;51(1):222-6
references.pmid: 1703033
references.citation: Urol Clin North Am. 1993 Nov;20(4):607-19
references.pmid: 7505968
references.citation: Bull Cancer. 1987;74(4):387-96
references.pmid: 2444292
references.citation: Clin Endocrinol (Oxf). 1977 Feb;6(2):95-104
references.pmid: 191221
references.citation: J Exp Med. 1968 Sep 1;128(3):387-98
references.pmid: 4299103
references.citation: Cancer Res. 1988 Oct 1;48(19):5422-6
references.pmid: 3166398
references.citation: Gan To Kagaku Ryoho. 1985 Dec;12(12):2379-86
references.pmid: 3865634
references.citation: J Clin Endocrinol Metab. 1969 Jan;29(1):63-71
references.pmid: 4883437